The Monash Institute of Pharmaceutical Sciences has announced the establishment of the National Centre for Biopharmaceutical Optimisation of mRNA Therapeutics (CORTx). Backed by the Medical Research Future Fund, the new national facility brings together researchers and industry to evaluate the delivery and biodistribution of new medicines into the body, a crucial step in the development of new mRNA therapeutics. CORTx will be led by co-directors Associate Professor Natalie Trevaskis and Associate Professor Angus Johnston, both mRNA Victoria Grant recipients and leaders within Victoria’s mRNA ecosystem. With partners including Moderna and iCamuno Biotherapeutics Pty Ltd, the centre can play a critical role in maximising the safety and efficacy of next generation mRNA medicines and vaccines #mRNA #research #investment #biotech
Congratulations to Associate Professor Natalie Trevaskis and Associate Professor Angus Johnston who are leading the new MRFF-backed National Centre for Biopharmaceutical Optimisation of mRNA Therapeutics (CORTx). Announced today, the new national facility will focus on a critical step in the development process for mRNA medicines, which is to evaluate delivery and biodistribution in the body, informing the plausibility of the candidate to progress toward human studies. This information is critical for maximising the potency, safety and manufacturability of mRNA medicines. Headquartered at the Monash Institute of Pharmaceutical Sciences, CORTx brings together academia and industry including partnerships with leading biotech companies, Moderna and iCamuno Biotherapeutics Pty Ltd, along with WEHI, The Australian National University, University of Melbourne, University of New South Wales and University of Queensland. CORTx joins a suite of mRNA initiatives being led by Monash University. We would also like to acknowledge mRNA Victoria for their ongoing support. To learn more about CORTx visit: https://lnkd.in/gYy9aPUW #mRNA #research #MIPS